Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> AMGEN Latest News

JAN 16, 2013 - Benzinga

A Must Read - Share

Amgen Says Top-Line Results from Phase 3 Aranesp RED-HF Trial Did Not Meet Primary Endpoint

Amgen (NASDAQ: AMGN) today announced top-line results of the Phase 3 Aranesp^® (darbepoetin alfa) RED-HF^® (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial.  The trial was initiated in 2006, and a total of 2,278 patients with symptomatic systolic heart failure and anemia (hemoglobin levels ranging from 9.0-12.0 g/dL) were rando

Tags: Amgen Says Top-Line Results from Phase 3 Aranesp RED-HF Trial Did Not Meet Primary Endpoint,  Amgen Latest News